Is bEACOPP , a new dose-escalated and accelerated regimen , at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin 's lymphoma : interim report from a trial of the German Hodgkin 's Lymphoma Study Group?
Combined with local irradiation, BEACOPP in one or both variants shows superior disease control compared with COPP/ABVD, with acceptable acute toxicity. Further follow-up is required to assess the effect of dosage and the effect on survival and late toxicities.
Concepts are used differently by various staff groups in a neonatal unit: this may have an impact on the effectiveness of computerised decision aids unless it is taken into account during their development.